Navion Neurosciences Closes $10.8 Million Seed Financing to Advance Precision Sodium-Channel Medicines for Epilepsy and Neuropathic Pain

Navion Neurosciences closed a $10.8 million seed financing to advance precision sodium-channel medicines targeting epilepsy and neuropathic pain. The funding supports early-stage development of the company’s neuroscience therapeutic programs, representing a positive private-market milestone but with limited broad public-market impact.